May 8, 2023
The DPX Delivery Platform Enables Cancer Vaccines to be Clinically Viable
IMV Inc (Nasdaq, TSX: IMV) is a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on our proprietary DPX® delivery platform to treat solid and hematologic cancers.
Our lead DPX-based immunotherapy, maveropepimut-S (MVP-S) provides the clinical and molecular proof of concept of the potential of our DPX technology in multiple cancer indications. Across all studies, MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers.
DPX-SurMAGE, another DPX-based immune-educating therapy, is a dual-targeted immunotherapy evaluated in a Phase 1 clinical trial in bladder cancer which was initiated in early 2022.
We believe the DPX technology versatility enables several practical advantages to DPX-based immunotherapies. As such, we are leveraging this platform to build a series of unique immune-educating cancer immunotherapies.
Near Term Clinical Readout With Our Validated Platform
Our goal is to move MVP-S forward on the path to registration trials in r/r DLBCL and ovarian cancer, while leveraging our versatile DPX platform to build a diversified portfolio of cancer immunotherapies.
*The Breast and Non-muscle invasive bladder cancer studies are neoadjuvant studies that will provide critical molecular and cellular PoC in this new clinical setting.
|Program||H1 2023||H2 2023|
Stage 1 Enrollment Completed & First Scan data
Stage 1 enrollment completed
First full cohort
|MVP-S and DPX-SurMAGE||Bladder* (NMIBC)||
MVP-S and DPX-SurMAGE
Pathologic response data